Return On Equity of Aclaris Therapeutics, Inc. from 30 Jun 2016 to 30 Sep 2025

Taxonomy & unit
ratio: %
Description
Return on equity can be defined as the amount of net income returned as a percentage of shareholders equity. Return on equity measures a corporation's profitability by revealing how much profit a company generates with the money shareholders have invested.
Summary
Aclaris Therapeutics, Inc. quarterly and annual Return On Equity in % history and change rate from 30 Jun 2016 to 30 Sep 2025.
  • Aclaris Therapeutics, Inc. Return On Equity for the quarter ending 30 Sep 2025 was -103%, a 291% decline year-over-year.
  • Aclaris Therapeutics, Inc. annual Return On Equity for 2024 was -94%, a 78% decline from 2023.
  • Aclaris Therapeutics, Inc. annual Return On Equity for 2023 was -53%, a 27% decline from 2022.
  • Aclaris Therapeutics, Inc. annual Return On Equity for 2022 was -42%, a 13% increase from 2021.
Return On Equity, Quarterly (%)
Return On Equity, YoY Quarterly Change (%)
Return On Equity, Annual (%)
Return On Equity, YoY Annual Change (%)

Aclaris Therapeutics, Inc. Quarterly Return On Equity (%)

Period Value YoY Chg Change % Start Date End Date
Q3 2025 -103% -76% -291% 01 Jul 2025 30 Sep 2025
Q2 2025 -96% -56% -141% 01 Apr 2025 30 Jun 2025
Q1 2025 -92% -44% -90% 01 Jan 2025 31 Mar 2025
Q4 2024 -94% -41% -78% 01 Oct 2024 31 Dec 2024
Q3 2024 -26% +38% +59% 01 Jul 2024 30 Sep 2024
Q2 2024 -40% +15% +27% 01 Apr 2024 30 Jun 2024
Q1 2024 -49% -2% -4.8% 01 Jan 2024 31 Mar 2024
Q4 2023 -53% -11% -27% 01 Oct 2023 31 Dec 2023
Q3 2023 -65% -25% -64% 01 Jul 2023 30 Sep 2023
Q2 2023 -54% -14% -36% 01 Apr 2023 30 Jun 2023
Q1 2023 -46% -7% -19% 01 Jan 2023 31 Mar 2023
Q4 2022 -42% +6% +13% 01 Oct 2022 31 Dec 2022
Q3 2022 -39% +15% +27% 01 Jul 2022 30 Sep 2022
Q2 2022 -40% +27% +40% 01 Apr 2022 30 Jun 2022
Q1 2022 -39% +68% +63% 01 Jan 2022 31 Mar 2022
Q4 2021 -48% +62% +56% 01 Oct 2021 31 Dec 2021
Q3 2021 -54% +49% +48% 01 Jul 2021 30 Sep 2021
Q2 2021 -67% +87% +57% 01 Apr 2021 30 Jun 2021
Q1 2021 -107% +52% +33% 01 Jan 2021 31 Mar 2021
Q4 2020 -110% +26% +19% 01 Oct 2020 31 Dec 2020
Q3 2020 -103% +14% +12% 01 Jul 2020 30 Sep 2020
Q2 2020 -154% -61% -65% 01 Apr 2020 30 Jun 2020
Q1 2020 -159% -81% -104% 01 Jan 2020 31 Mar 2020
Q4 2019 -136% -64% -89% 01 Oct 2019 31 Dec 2019
Q3 2019 -117% -54% -86% 01 Jul 2019 30 Sep 2019
Q2 2019 -93% -45% -92% 01 Apr 2019 30 Jun 2019
Q1 2019 -78% -37% -90% 01 Jan 2019 31 Mar 2019
Q4 2018 -72% -38% -110% 01 Oct 2018 31 Dec 2018
Q3 2018 -63% -32% -104% 01 Jul 2018 30 Sep 2018
Q2 2018 -49% -14% -42% 01 Apr 2018 30 Jun 2018
Q1 2018 -41% -3% -8.3% 01 Jan 2018 31 Mar 2018
Q4 2017 -34% +11% +24% 01 Oct 2017 31 Dec 2017
Q3 2017 -31% +17% +35% 01 Jul 2017 30 Sep 2017
Q2 2017 -34% +38% +53% 01 Apr 2017 30 Jun 2017
Q1 2017 -38% 01 Jan 2017 31 Mar 2017
Q4 2016 -45% 01 Oct 2016 31 Dec 2016
Q3 2016 -48% 01 Jul 2016 30 Sep 2016
Q2 2016 -72% 01 Apr 2016 30 Jun 2016

Aclaris Therapeutics, Inc. Annual Return On Equity (%)

Period Value YoY Chg Change % Start Date End Date
2024 -94% -41% -78% 01 Jan 2024 31 Dec 2024
2023 -53% -11% -27% 01 Jan 2023 31 Dec 2023
2022 -42% +6% +13% 01 Jan 2022 31 Dec 2022
2021 -48% +62% +56% 01 Jan 2021 31 Dec 2021
2020 -110% +26% +19% 01 Jan 2020 31 Dec 2020
2019 -136% -64% -89% 01 Jan 2019 31 Dec 2019
2018 -72% -38% -110% 01 Jan 2018 31 Dec 2018
2017 -34% +11% +24% 01 Jan 2017 31 Dec 2017
2016 -45% 01 Jan 2016 31 Dec 2016
* An asterisk sign (*) next to the value indicates that the value is likely invalid.